Clinical Trial

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

Study acronym: #HOPE4KIDNEY
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-04-06; most recent amendment 2026-06-18.
Status change: Recruiting → Active, Not Recruiting 2025-05-30
Status change: Not Yet Recruiting → Recruiting 2023-11-02
Trial Details
NCT Number NCT05820087
Lead Sponsor HistoSonics, Inc.
Conditions Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Enrollment 67 participants
Start Date 2024-01-04
Primary Completion 2025-09-04 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-23